Compare Global X Copper Miners ETF (COPX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Summit Therapeutics Inc — how do they compare? Global X Copper Miners ETF trades at $85.69 (market cap $7.10B), while Summit Therapeutics Inc trades at $17.32 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Summit Therapeutics Inc for 16 Days on average.
| COPX | SMMT | |
|---|---|---|
Market Cap | $7.10B | $13.71B |
Volume | 2,871,128 | 6,173,057 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $26.38 |
52-Week Low | $57.43 | $12.43 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $84.83, up 1.5% today, but technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The ETF faces resistance at $85 with support at $79. Recent news highlights copper's strategic importance for AI infrastructure and electrification, though analysts express caution about near-term global surplus projections despite strong copper price fundamentals.
The copper miner ETF offers exposure to the AI-driven copper demand story but faces headwinds from Federal Reserve policy uncertainty and potential global supply surpluses. While long-term electrification trends support the investment thesis, near-term volatility and miner underperformance relative to copper prices present both opportunity and risk for investors.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
